ArticleSkin appendage disorders2025
Male Pattern Androgenetic Alopecia Linked to an Adrenal Tumor: A Case Report.
Article in Skin appendage disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Androgenetic alopecia (AGA) is a type of hair loss that often manifests as male or female pattern baldness. In women, AGA resembling male pattern baldness can occur in conditions of hyperandrogenism, such as congenital adrenal hyperplasia or ovarian and adrenal tumors, which are exceedingly rare, occurring in approximately 0.2% of cases. Case Presentation: We report a 62-year-old female exhibiting hair loss and hirsutism that began over a decade ago. The medical examination reveals hirsutism on the face, abdomen, and chest, and hair loss in the fronto-parieto-occipital region, with a male pattern distribution consistent with grade VII on the Hamilton scale. Trichoscopy revealed loss of follicular openings, single follicular units, miniaturized hairs, and perifollicular brown halo. Laboratory tests indicated a total testosterone level of 10.15 ng/mL. An abdominal CT scan revealed bilateral adrenal adenomas, which were subsequently treated with laparoscopic radical adrenalectomy. Conclusion: In postmenopausal women, a new-onset state of hyperandrogenism may lead to virilizing symptoms, such as male pattern alopecia, when testosterone levels exceed 5 nmol/L, necessitates immediate investigation to exclude an androgen-producing tumor, which typically normalizes swiftly within weeks post-surgery, while symptoms of androgen excess gradually diminish following the normalization of testosterone levels, as observed in our case. Identifying the cause of hyperandrogenism is crucial for treatment. Surgery remains the primary option for postmenopausal women with virilizing symptoms and androgen excess.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.